A new therapy to re-activate silenced genes in patients who suffer from neurodegenerative diseases or stroke is being developed by researchers at the University of Illinois at Chicago and Cornell University.
Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage non-small cell lung cancer (NSCLC), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).
Researchers exploring the notion that certain nutrients might protect against pancreatic cancer found that lean individuals who got most of these nutrients from food were protected against developing cancer. The study also suggests this protective effect does not hold true if the nutrients come from vitamin supplements.
People who use Swedish moist snuff (snus) run twice the risk of developing cancer of the pancreas. This is the main result of a follow-up study conducted by Karolinska Institutet researchers amongst almost 300,000 male construction workers. The study is published today online in the prestigious medical journal The Lancet.
Scientists have discovered a way to distinguish pancreatic cancer from non-cancerous tissue, new research shows. The method may also distinguish patients who will survive longer than two years.
While new findings from Ohio State University scientists suggest a genetic marker that could help distinguish between chronic pancreatitis and pancreatic cancer and gauge who will do well with cancer treatment, a pharmacologist at the Kimmel Cancer Center at Jefferson in Philadelphia sees the discovery as much more.
An anti-reflux valve developed to help esophageal cancer patients also has been shown to help those with bile duct obstruction, according to Kulwinder S. Dua, M.D., a research physician at the Medical College of Wisconsin in Milwaukee.
Results from a Phase I study of a pancreatic cancer vaccine may offer clues toward promoting long-term survival from the disease, according to researchers from the University of Pittsburgh Cancer Institute.
A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.
A new study from the University of Pittsburgh Cancer Institute suggests that a commonly used herbal supplement, triphala, has cancer-fighting properties that prevent or slow the growth of pancreatic cancer tumors implanted in mice.